This site is intended for US healthcare professionals only

For unresectable, locally advanced or metastatic, MALIGNANT PLEURAL MESOTHELIOMA (MPM),¹

Optune Lua^® delivers the power of TTFields therapy to attack MPM cells where they're vulnerable^1-3

Consider Optune Lua for your next patient with MPM

STELLAR clinical results: Patients who used Optune Lua first line together with pemetrexed + cisplatin or carboplatin achieved 18.2 months median OS with no added systemic AEs^1,2

STELLAR: PRIMARY ENDPOINT

median OS (95.5% CI: 12.1-25.8)

in a population that included patients with epithelioid and nonepithelioid histologies

Optune Lua approval was based on the STELLAR study: a prospective, multicenter, single-arm, phase 2 study designed to study the safety and efficacy of Optune Lua and pemetrexed + cisplatin or carboplatin first line in patients with unresectable, locally advanced or metastatic, MPM. Optune Lua was approved under the Humanitarian Device Exemption (HDE) pathway.^1,2

No systemic AEs were considered to be related to the use of Optune Lua^1,2

The only AE attributed to the use of Optune Lua was skin irritation (71% of patients); 66% mild-to-moderate and 5% severe. No SAEs were considered related to device use.

View STELLAR efficacy outcomes

View STELLAR safety results

Optune Lua uses electrical fields to disrupt cancer cell viability without affecting healthy cells.¹

Explore how Optune Lua delivers TTFields, which exert antitumor effects by disrupting the activity of cancer cells during multiple phases of mitosis^1,4

How does it work?

Discover the innovation of Optune Lua

Optune Lua is a noninvasive and wearable treatment that can provide continuous anticancer therapy.^1,3*

What is Optune Lua?

Submit a prescription and we take care of the rest

Personalized support from Day 1, from device training to reimbursement assistance and more

Contact MyNovocure to learn more

MyNovocure Care coordinator, Kate, providing phone support

Next: FDA Approval

^*Continuous treatment requires patient to be wearing the powered device.

AE, adverse event; OS, overall survival; SAE, serious adverse event; TTFields, Tumor Treating Fields.

References: 1. Optune Lua. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021. 2. Ceresoli GL, Aerts JG, Dziadziuszko R. et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20(12):1702-1709. doi:10.1016/S1470-2045(19)30532-7 3. Mumblat H, Martinez-Conde A, Braten O, et al. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models. Lung Cancer. 2021:160:99-110. doi:10.1016/j.lungcan.2021.08.011. Epub 2021 Aug 27. 4. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64(9):3288-95. doi:10.1158/0008-5472.can-04-0083

Important Safety Information

Contraindications

Do not use Optune Lua in patients with implantable electronic medical devices such as pacemakers or implantable automatic defibrillators, etc. Use of Optune Lua together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure^®.

The most common (≥10%) adverse events involving Optune Lua in combination with chemotherapy were anemia, constipation, nausea, asthenia, chest pain, fatigue, medical device site reaction, pruritus, and cough.

Other potential adverse effects associated with the use of Optune Lua include: treatment related skin toxicity, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical device site reaction and skin breakdown/skin ulcer.

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

Do not prescribe Optune Lua for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established.

Please click here to see Optune Lua Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Optune Lua® delivers the power of TTFields therapy to attack MPM cells where they're vulnerable1-3

STELLAR clinical results: Patients who used Optune Lua first line together with pemetrexed + cisplatin or carboplatin achieved 18.2 months median OS with no added systemic AEs1,2

Optune Lua uses electrical fields to disrupt cancer cell viability without affecting healthy cells.1